EXEL Stock Overview
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.76|
|52 Week High||US$24.69|
|52 Week Low||US$15.50|
|1 Month Change||-21.28%|
|3 Month Change||-9.20%|
|1 Year Change||-27.39%|
|3 Year Change||-12.77%|
|5 Year Change||-8.22%|
|Change since IPO||16.94%|
Recent News & Updates
Exelixis: Becoming A Giant Pharma
Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blockbuster to grow by several more folds in revenue in the next few years. Meanwhile, a vast number of younger pipeline assets ensures that Exelixis could become a pharmaceutical giant of the future.
Exelixis: Beyond The Cabozantinib Franchise
Driven by their blockbuster Cabo, Exelixis generated $1.43B in total revenues translating to a 45.3% year-over-year (YOY) increase. For further growth, the company is expanding Cabo's label in multiple ongoing Phase 3 investigations. Aside from Cabo, Exelixis is tinkering with small molecules, antibody-drug conjugates and other biotherapeutics that are addressing highly promising targets.
|EXEL||US Biotechs||US Market|
Return vs Industry: EXEL underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: EXEL underperformed the US Market which returned -12.9% over the past year.
|EXEL Average Weekly Movement||5.7%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: EXEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: EXEL's weekly volatility (6%) has been stable over the past year.
About the Company
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis Fundamentals Summary
|EXEL fundamental statistics|
Is EXEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXEL income statement (TTM)|
|Cost of Revenue||US$52.88m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.93|
|Net Profit Margin||19.60%|
How did EXEL perform over the long term?See historical performance and comparison
Is Exelixis undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXEL ($17.76) is trading below our estimate of fair value ($74.93)
Significantly Below Fair Value: EXEL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXEL is poor value based on its PE Ratio (19.1x) compared to the US Biotechs industry average (15.1x).
PE vs Market: EXEL is poor value based on its PE Ratio (19.1x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: EXEL is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: EXEL is overvalued based on its PB Ratio (2.5x) compared to the US Biotechs industry average (1.5x).
How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXEL's forecast earnings growth (24.7% per year) is above the savings rate (1.9%).
Earnings vs Market: EXEL's earnings (24.7% per year) are forecast to grow faster than the US market (12.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXEL's revenue (11.4% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: EXEL's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (17.9%).
How has Exelixis performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXEL has high quality earnings.
Growing Profit Margin: EXEL's current net profit margins (19.6%) are higher than last year (6.3%).
Past Earnings Growth Analysis
Earnings Trend: EXEL's earnings have declined by 2.1% per year over the past 5 years.
Accelerating Growth: EXEL's earnings growth over the past year (360.1%) exceeds its 5-year average (-2.1% per year).
Earnings vs Industry: EXEL earnings growth over the past year (360.1%) exceeded the Biotechs industry 96.9%.
Return on Equity
High ROE: EXEL's Return on Equity (13%) is considered low.
How is Exelixis's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($1.8B) exceed its short term liabilities ($289.1M).
Long Term Liabilities: EXEL's short term assets ($1.8B) exceed its long term liabilities ($71.2M).
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL has no debt compared to 5 years ago when its debt to equity ratio was 93.4%.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.
What is Exelixis's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EXEL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Morrissey (60 yo)
Dr. Michael M. Morrissey, Ph D., also known as Mike, has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as Independent Director at Vera Therapeutics,...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD7.53M) is about average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Mike's compensation has increased by more than 20% in the past year.
Experienced Management: EXEL's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: EXEL's board of directors are seasoned and experienced ( 18 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EXEL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Exelixis, Inc.'s employee growth, exchange listings and data sources
- Name: Exelixis, Inc.
- Ticker: EXEL
- Exchange: NasdaqGS
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.696b
- Shares outstanding: 320.74m
- Website: https://www.exelixis.com
Number of Employees
- Exelixis, Inc.
- 1851 Harbor Bay Parkway
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.